Loading...
Loading...
Also known as: Mounjaro, Zepbound, GIP/GLP-1 RA
A dual GIP/GLP-1 receptor agonist that has shown superior weight loss and metabolic outcomes compared to semaglutide in head-to-head trials.
Tirzepatide is a first-in-class dual incretin agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Approved as Mounjaro for type 2 diabetes and Zepbound for obesity, it has demonstrated unprecedented weight loss results.
The SURPASS-2 trial showed tirzepatide was superior to semaglutide 1mg for HbA1c reduction and weight loss at all doses tested. The SURMOUNT trials showed weight loss approaching surgical outcomes.
Tirzepatide activates both GIP and GLP-1 receptors with a biased agonism profile. GIP receptor activation enhances fat metabolism and insulin sensitivity, while GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion.
Typical Dose
2.5-15mg
Frequency
Weekly
Cycle Length
Ongoing (chronic use)
Half-Life
~5 days
FDA-approved (Mounjaro, Zepbound). Extensive Phase III data (SURPASS, SURMOUNT programs).
Common: nausea, diarrhea, vomiting (usually transient, dose-dependent). Similar safety profile to GLP-1 agonists. Same thyroid cancer boxed warning as semaglutide. Do not use during pregnancy.
A 15-amino-acid peptide derived from human gastric juice with potent tissue-healing and anti-inflammatory properties.
Fertility Preservation: Maintains testosterone and spermatogenesis during TRT.
Potential Benefits: Increases in lean body mass, reductions in adipose tissue, improved metabolic parameters.